Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Read more here.
Coherent Market Insights has announced new analysis on Antibodies Market Status 2022-2028 which has been prepared based on an in-depth market analysis
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Astrazeneca, Biocytogen, Bionomics, Cristal, Emergex, Eterna, Eucure, Eureka, Exacis, GSK, Ikena, Merck & Co., Mereo, Synaffix, Syncromune, Tempus, Treventis, Tvax.
Mereo BioPharma Group plc , a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the U.S. Food and Drug Administration has granted Fast... | October 18, 2022
Ultragenyx Pharmaceutical (NASDAQ:RARE) Sets New 1-Year Low on Insider Selling
New Jersey, United States - The Global Ornithine-Transcarbamylase Deficiency market is expected
Designation Validates Alvelestat’s Potential to Address a Serious Unmet Need
ImmunityBio operates an effective development program for infectious disease and oncology therapies. Read why IBRX should only be considered by experienced biotech investors.
Form DEF 14A Anebulo Pharmaceuticals, For: Oct 17 StreetInsider.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Rating) CFO Mardi Dier sold 3,484 shares of the firm’s stock in a transaction that occurred on Wednesday, October 12th. The stock was sold at an average price of $38.22, for a total transaction of $133,158.48. Following the sale, the chief financial…
Ultragenyx Pharmaceutical Inc (RARE) Stock Falls -1.34% This Week: Is It a Good Pick?
North American Morning Briefing: All Eyes on Bank -2- Morningstar
Friday’s top analyst upgrades and downgrades included Altice USA, Apple, Colgate-Palmolive, Marathon Petroleum, Mastercard, Medtronic, Meta Platforms, Nike, Prologis, Realty Income, SLM, Tenaris and Visa.
Guggenheim raised Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating in a research note on Thursday.
| October 13, 2022
| October 13, 2022
Upgrades
Urea Cycle Disorders Treatment Market Research focuses on the key trends prevailing in the Global Urea Cycle Disorders Treatment Industry sector. The
Mucopolysaccharidosis refers to a group of inherited conditions in which the body is unable to properly breakdown mucopolysaccharides,
Carlsbad, CA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announced the election of its 2023 Officers, Executive Committee, a…